Skip to main content

Table 1 Percentage of H-460 cells in late or early apoptosis at the end of treatment period either with doxorubicin or P276-00 alone or in the combination of doxorubicin followed by P276-00

From: Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Treatment group

Percentage of cells

 

Live cells

Annexin +ve

Annexin + PI

PI +ve

Control

90.5

3

4

2.3

Doxorubicin ( 100 nM)

60

30.4

8.6

1

P276-00 (1200 nM)

53

38.5

8.2

0.3

Doxorubicin> P276-00

14.1

50.2

34.3

2